Skip to main content

Table 3 Frequency of TEAEs Occurring at ≥5% or Any Statistically Significant Events

From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

Event Term White
N = 600
N (%)
Black
N = 369
N (%)
Total
N = 969
N (%)
p-value * P = value **
Somnolence 88 (14.7) 52 (14.1) 140 (14.4) 0.851 0.792
Headache 76 (12.7) 62 (16.8) 138 (14.2) 0.088 0.057
Weight Increased 72 (12.0) 62 (16.8) 134 (13.8) 0.044 0.031
Insomnia 64 (10.7) 26 (7.0) 90 (9.3) 0.068 0.050
Anxiety 61 (10.2) 23 (6.2) 84 (8.7) 0.035 0.216
Dry Mouth 57 (9.5) 33 (8.9) 90 (9.3) 0.820 0.785
Nausea 47 (7.8) 27 (7.3) 74 (7.6) 0.804 0.858
Sedation 47 (7.8) 22 (6.0) 69 (7.1) 0.305 0.223
Increased Appetite 41 (6.8) 32 (8.7) 73 (7.5) 0.317 0.542
Depression 40 (6.7) 19 (5.1) 59 (6.1) 0.407 0.369
Fatigue 38 (6.3) 19 (5.1) 57 (5.9) 0.485 0.205
Neopharyngitits 36 (6.0) 15 (4.1) 51 (5.3) 0.236 0.165
Vomiting 35 (5.8) 13 (3.5) 48 (5.0) 0.127 0.154
Dizziness 32 (5.3) 20 (5.4) 52 (5.4) 1.000 0.791
Akathesia 31 (5.2) 11 (3.0) 42 (4.3) 0.143 0.230
Diarrhoea 31 (5.2) 24 (6.5) 55 (5.7) 0.394 0.375
Tremor 31 (5.2) 7 (1.9) 38 (3.9) 0.010 0.019
Disturbance in Attention 13 (2.2) 1 (0.3) 14 (1.4) 0.023 0.028
Irritability 12 (2.0) 0 (0.0) 12 (1.2) 0.005 0.012
Chills 8 (1.3) 0 (0.0) 8 (0.8) 0.027 0.032
Initial Insomnia 7 (1.2) 0 (0.0) 7 (0.7) 0.049 0.046
Migraine 1 (0.2) 4 (1.1) 5 (0.5) 0.073 0.033
Cyst 0 (0.0) 3 (0.8) 3 (0.3) 0.055 0.022
Left Ventricular Hypertrophy 0 (0.0) 2 (0.5) 2 (0.2) 0.145 0.017
Leukopenia 0 (0.0) 2 (0.5) 2 (0.2) 0.145 0.006
  1. *Fisher Exact Test; **CMH Test adjusted for protocol
  2. Abbreviation: N = number of randomized patients who have taken at least 1 dose of study drug and have a post-baseline visit; TEAEs = treatment-emergent adverse events